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Duration ofMenopausal Vasomotor Symptoms
Over theMenopause Transition
Nancy E. Avis, PhD; Sybil L. Crawford, PhD; Gail Greendale, MD; Joyce T. Bromberger, PhD;
Susan A. Everson-Rose, PhD, MPH; Ellen B. Gold, PhD; Rachel Hess, MD; Hadine Joffe, MD, MSc;
HowardM. Kravitz, DO, MPH; Ping G. Tepper, PhD; Rebecca C. Thurston, PhD;
for the Study of Women’s Health Across the Nation (SWAN)
IMPORTANCE The expected duration of menopausal vasomotor symptoms (VMS) is
important to womenmaking decisions about possible treatments.
OBJECTIVES To determine total duration of frequent VMS (6 days in the previous 2 weeks)
(hereafter total VMS duration) during themenopausal transition, to quantify how long
frequent VMS persist after the final menstrual period (FMP) (hereafter post-FMP
persistence), and to identify risk factors for longer total VMS duration and longer post-FMP
persistence.
DESIGN, SETTING, AND PARTICIPANTS The Study ofWomen’s Health Across the Nation
(SWAN) is a multiracial/multiethnic observational study of themenopausal transition among
3302women enrolled at 7 US sites. From February 1996 through April 2013, women
completed amedian of 13 visits. Analyses included 1449womenwith frequent VMS.
MAIN OUTCOMES ANDMEASURES Total VMS duration (in years) (hot flashes or night sweats)
and post-FMP persistence (in years) into postmenopause.
RESULTS Themedian total VMS duration was 7.4 years. Among 881 womenwho experienced
an observable FMP, themedian post-FMP persistence was 4.5 years. Womenwhowere
premenopausal or early perimenopausal when they first reported frequent VMS had the
longest total VMS duration (median, >11.8 years) and post-FMP persistence (median, 9.4
years). Womenwhowere postmenopausal at the onset of VMS had the shortest total VMS
duration (median, 3.4 years). Compared with women of other racial/ethnic groups, African
American women reported the longest total VMS duration (median, 10.1 years). Additional
factors related to longer duration of VMS (total VMS duration or post-FMP persistence) were
younger age, lower educational level, greater perceived stress and symptom sensitivity, and
higher depressive symptoms and anxiety at first report of VMS.
CONCLUSIONS AND RELEVANCE Frequent VMS lastedmore than 7 years during the
menopausal transition for more than half of the women and persisted for 4.5 years after the
FMP. Individual characteristics (eg, being premenopausal and having greater negative
affective factors when first experiencing VMS) were related to longer-lasting VMS. Health
care professionals should counsel women to expect that frequent VMS could last more than 7
years, and theymay last longer for African American women.
JAMA Intern Med. 2015;175(4):531-539. doi:10.1001/jamainternmed.2014.8063
Published online February 16, 2015.
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V asomotor symptoms (VMS), including hot flashes andnight sweats, are hallmarks of themenopausal transi-tion (MT) and can significantly affect quality of life.1-3
Up to 80% of women experience VMS during the MT,4,5 and
most rate them as moderate to severe.6 Vasomotor symp-
toms are one of the chief menopause-related problems for
whichUSwomen seekmedical treatment.7,8 Results from the
Study of Women’s Health Across the Nation (SWAN) suggest
that VMS are also independently associatedwithmultiple in-
dicatorsofelevatedcardiovascular risk9,10andgreaterbone loss
and higher bone turnover.11
Despite their pervasiveness, negative influence on qual-
ity of life, and association with adverse health indicators,
we lack robust estimates of how long VMS last. According to
a recent American College of Obstetricians and Gynecolo-
gists report,12 previous clinical guidelines suggested that
most women experience hot flashes from 6 months to 2
years, but epidemiological studies6,13,14 cast doubt on these
figures, finding durations between 5 and 13 years. Although
mounting evidence suggests that VMS last much longer
than originally presumed, current estimates of VMS dura-
tion are limited in part because of cross-sectional data or
insufficient follow-up of women after the final menstrual
period (FMP).
As a longitudinal study spanning 17 years, SWAN is posi-
tioned to provide more accurate estimates of VMS duration.
SWANhas assessed a large cohort ofwomenover 14 studyvis-
its as they transitioned frompremenopauseorearlyperimeno-
pause into late postmenopause.
These analyses sought (1) to determine total duration of
frequent VMS (defined as ≥6 days in the previous 2 weeks)
(hereafter total VMS duration) during theMT (defined as the
entire follow-upperiod frompremenopauseorearlyperimeno-
pause and as far into postmenopause as eachwomanwas ob-
served); (2) to quantify how long frequent VMS persist after
theFMP(hereafterpost-FMPpersistence) (ie, starting fromthe
lastmenstrualperioddateandextendingas far intopostmeno-
pause as each woman was observed); and (3) to identify risk
factors for longer totalVMSdurationand longerpost-FMPper-
sistence. We focused on frequent VMS because women re-
port these as most bothersome.15
Methods
Sample and Procedures
SWAN is a multiracial/multiethnic observational study char-
acterizing biological andpsychosocial changes occurringdur-
ing the MT.16 Briefly, from 1995 to 1997, each clinical site re-
cruited women of non-Hispanic white race/ethnicity and
women belonging to predetermined racial/ethnic minorities.
The latter included African American women in Pittsburgh,
Pennsylvania, Boston, Massachusetts, Chicago, Illinois, and
Ypsilanti,Michigan; Japanesewomen inLosAngeles, Califor-
nia; Hispanic women in Newark, New Jersey; and Chinese
women in Oakland, California. Protocols were approved
by institutional review boards at each site. All participants
provided written informed consent.
Baseline eligibility included age between 42 and 52 years,
presenceofan intactuterusandat least 1ovary, reportofamen-
strual cycle in the 3 months before screening, and absence of
pregnancy, lactation, or use of oral contraceptives or hormone
therapy(HT).Amongcohort-eligiblewomen,50.7%enteredthe
longitudinal study.16 Participants were assessed in person at
baselineandapproximatelyannually throughfollow-upvisit 13
from February 1996 through April 2013 (mean and maximum
follow-up durations were 12.7 and 17.2 years, respectively). A
standardizedprotocolofdetailedquestionswasusedabouttheir
lifestyle and psychosocial factors, physical and psychological
symptoms, anthropometric measurements, and medical, re-
productive, andmenstrualhistory.All instrumentswere trans-
lated into Spanish, Japanese, and Cantonese.
Analyses of total VMSduration includedwomen reporting
frequentVMS(≥6days in theprevious2weeks) at 1ormorevis-
its. The analytic sample of 1449 women was based on the fol-
lowingexclusions from3302cohortparticipantsatbaselineen-
rolled at 7 US sites: hysterectomy or bilateral oophorectomy
during SWAN (n = 330), initiation of HT on or before first re-
portof frequentVMS(n = 583), andnovisitswith frequentVMS
(n = 940) (Figure 1). Analyses of post-FMP persistence of fre-
quentVMSwere conducted inwomenwith a knownFMPdate
who reported frequent VMS at 1 or more visits occurring after
the FMP. The FMP was defined retrospectively as the date of
lastmenses preceding 12months of amenorrhea. Among 1449
women included in analyses of total VMS duration, the FMP
could not be dated in 406women, 132women reported no fre-
quentVMSafter theFMP,and30womenstartedHTbefore their
first post-FMP report of frequent VMS for a sample size of 881
women for post-FMP persistence.
Main Outcomes andMeasures
Hot flashes and night sweats in the past 2 weeks were as-
sessed separately via questionnaire at each visit and re-
corded as occurring not at all, 1 to 5 days, 6 to 8 days, 9 to 13
Figure 1. Consolidated Standards of Reporting Trials Study FlowDiagram
1449 Total VMS duration
sample
3302 Baseline cohort
881 Post-FMP persistence
sample
1853 Excluded
940 No visits with frequent VMS
583 Initiation of HT on or before first report of VMS
330 Hysterectomy or bilateral oophorectomy
568 Excluded
406 FMP could not be dated
132 No frequent VMS after the FMP
30 Started HT before first post-FMP report of VMS
FMP indicates final menstrual period; HT, hormone therapy;
and VMS, vasomotor symptoms.
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days, or every day. Frequent VMSwere defined as hot flashes
ornightsweatsoccurringat least6days in theprevious2weeks.
Earlier SWAN data have shown that experiencing VMS for at
least 6 days is highly related to anxiety,17 depression,18 sleep
disturbances,19qualityof life,20 cardiovascular risk,10,21-23 bone
health,11,24 and VMS bothersomeness.15
Primary outcomeswere (1) total VMSduration (starting at
anypointduring theobservationperiod) and (2)post-FMPper-
sistence of frequent VMS (frequent VMS at any point after the
FMP). Total VMS durationwas calculated as years elapsed be-
tween the first and last report of frequentVMS. Post-FMPper-
sistencewas calculated as years elapsed between the first and
last report of frequentVMSoccurring after theFMP. Forwom-
en reporting frequentVMSat a single visit, total VMSduration
wasassignedas0.5year,similar toworkbyFreemanetal14 (Mary
Sammel,writtencommunication,February8,2012).Forconsis-
tency,weadded0.5year to totaldurationand topost-FMPper-
sistenceforallparticipants.CessationofVMSwasdefinedasthe
occurrenceof 2 consecutivevisitswithoutHTuseandwithout
report of frequent VMS, as in the study by Freeman et al.
Covariates includedsociodemographiccharacteristics, life-
style behaviors, anthropometrics, andpsychosocial variables
related toprevalent or incidentVMS.5 Variables assessedonly
atbaseline (eg, race/ethnicity)orcollectedrepeatedlybutstable
over time (eg, smoking)were obtained from thebaseline visit,
whileother time-varyingvariableswereobtained fromthe first
visit at which frequent VMSwere reported (Table 1). Sociode-
mographic characteristics were age, self-reported race/
ethnicity, site (among 7 US sites), married or partnered sta-
tus, financial strain (ie, difficulty paying for basics), and
educational level.
Lifestyle and anthropometric variableswere assessed, in-
cluding smoking and body mass index (BMI). Also evaluated
were sports physical activity25,26 and alcohol servings per
week.27
Psychosocial variableswere recorded. These included at-
titudes toward menopause,28 symptom sensitivity (summed
score of 5 items assessing heightened attention to bodily
sensations),29 anxiety (summed score of the number of days
in thepast2weeks inwhich4symptoms[irritabilityorgrouchi-
ness, tensenessornervousness, poundingor racingheart, and
fearfulness fornoreason]wereexperienced),17perceivedstress
(summed score of 4 items,with the total score ranging from 5
[never] to 25 [fairly often]),30 depressive symptoms (score of
≥16 on the Center for Epidemiologic Studies–Depression
Scale),31 and emotional and instrumental social support (4-
item summed scale).32
TheMTstage at the first visit atwhich frequentVMSwere
reported was obtained from self-reported bleeding patterns
during theprecedingyear.Thisvariablewascategorizedaspre-
menopausal (bleeding in the previous 3 months, with no
change in menstrual regularity in the past year), early peri-
menopausal (bleeding in the previous 3months and changes
inmenstrual regularity in the past year), late perimenopausal
(amenorrhea in theprevious 3monthsbutbleeding in thepast
year), or postmenopausal (>12 months of amenorrhea).5
Women with menstrual bleeding since the prior visit were
asked for thedateof themost recentmenses.Analysesofpost-
FMP persistence of VMS included age at the FMP, which was
calculated based on the last bleeding date.
Statistical Analysis
Characteristics of the 2 analytic samples (total VMS duration
and post-FMP persistence) were summarized using frequen-
cies, means, and SDs. The unadjusted associations of covari-
ateswith totalVMSdurationorpost-FMPpersistencewere as-
sessedusingKaplan-Meier analyses and log-rankPvalues.33,34
Forwomen notmeeting the criterion for VMS cessation, total
VMSduration andpost-FMPpersistencewere censored atHT
initiationorafter theendofaparticipant’sdatacollection.Total
VMS duration also was censored for women reporting fre-
quent VMS at study baseline becausewe could infer only that
their duration was at least as long as our duration observed
herein.
The adjusted associations of total VMS duration or post-
FMP persistence with covariates and corresponding adjusted
median durations were estimated from Cox proportional haz-
ards regressionmodels.Backwardeliminationwasusedtoomit
redundant or unrelated predictors (P > .05), forcing in race/
ethnicity and site as design variables. Proportionality of haz-
ards was assessed by testing the significance of each predic-
tor’s interactionwith totalVMSduration,35 by considerationof
model fit as indicated by the Akaike information criterion
statistic,36 and by plots of residuals and transformed hazard
estimates.37Nononproportionalhazardswere identified.Con-
tinuous covariates were categorized to allow for possible non-
linear associations. Because data collection at the Newark site
was suspended during annual follow-ups 6 through 8, 10, and
11, we ran sensitivity analyses that excluded participants from
this site, and resultswere similar.Wealso ran secondaryanaly-
sesof totalVMSdurationandpost-FMPpersistenceofanyVMS
in the past 2 weeks. Because patterns of association of covari-
ates with total VMS duration and post-FMP persistence were
similar for any VMS and for frequent VMS, we report only re-
sults for frequent VMS for brevity and clinical relevance. Re-
sults are presented as hazard ratios (95% CIs) and as the me-
diantotalVMSdurationorpost-FMPpersistence.Forsubgroups
whosemediancouldnotbeestimatedbecause too fewwomen
hadceasedhavingfrequentVMS,resultsarepresentedasgreater
than the longest observed (noncensored) total VMS duration.
Results
Characteristics of each sample are summarized in Table 1. The
unadjustedmediantotalVMSdurationwas7.4years (Figure2A).
Women who were premenopausal or early perimenopausal
whentheyfirst reportedfrequentVMShadthelongest totalVMS
duration (median, >11.8 years) and post-FMP persistence (me-
dian, 9.4 years).Womenwhowere postmenopausal at the on-
set of VMS had the shortest total VMS duration after the FMP
(median, 3.4 years; P < .001). The median total VMS duration
variedsignificantlybyrace/ethnicity (P < .001) (Figure2B).Afri-
canAmericanwomen reported the longest total VMSduration
(median, 10.1years), andJapaneseandChinesewomenhadthe
shortest total VMS durations (median, 4.8 and 5.4 years, re-
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spectively). Themedian total VMSdurationswere6.5 years for
non-Hispanicwhitewomenand8.9years forHispanicwomen.
Except for Chinese vs Japanese women, all pairwise racial/
ethnic differences were statistically significant (P < .05). Total
VMSdurationwasalsosignificantly longer inthosewithyounger
age at first report of VMS, in ever smokers, and inwomenwith
greater BMI and higher symptom sensitivity, anxiety, per-
ceivedstress,anddepressivesymptoms.TotalVMSdurationwas
significantly shorter inwomenwhowere currentlymarried or
partnered, inwomenwhohadhighereducational level and less
financial strain, and inwomenwhohadgreater social support.
Neither sports physical activity nor alcohol servings per week
were statistically significant.
The unadjusted median post-FMP persistence was 4.5
years.Associationswithparticipant characteristicswere simi-
lar to those for total VMS duration except formarried or part-
Table 1. Characteristics of the Study ofWomen’s Health Across the Nation (SWAN) Participants in Analyses
of Total VMSDuration and Post-FMP Persistencea
Characteristic
Total VMS Duration
(n = 1449)
Post-FMP Persistence
(n = 881)
Age, mean (SD), yb 50.2 (3.9) 51.1 (3.7)
Menopausal transition stage, No. (%)b (n = 1440) (n = 879)
Premenopause 183 (12.7) 72 (8.2)
Early perimenopause 700 (48.6) 348 (39.6)
Late perimenopause 266 (18.5) 191 (21.7)
Postmenopause 291 (20.2) 268 (30.5)
Race/ethnicity, No. (%)
African American 479 (33.1) 310 (35.2)
Non-Hispanic white 652 (45.0) 380 (43.1)
Chinese 95 (6.6) 65 (7.4)
Hispanic 109 (7.5) 50 (5.7)
Japanese 114 (7.9) 76 (8.6)
Married or partnered status, No./Total (%)b 971/1403 (69.2) 591/850 (69.5)
Financial strain, No. (%)c (n = 1436) (n = 873)
Very hard to pay for basics 152 (10.6) 90 (10.3)
Somewhat hard 441 (30.7) 266 (30.5)
Not at all hard 843 (58.7) 517 (59.2)
Education level, No. (%)c (n = 1437) (n = 875)
<College 878 (61.1) 527 (60.2)
≥College 559 (38.9) 348 (39.8)
Smoking, No. (%)c (n = 1440) (n = 876)
Never 770 (53.5) 485 (55.4)
Past 389 (27.0) 232 (26.5)
Current 281 (19.5) 159 (18.2)
BMI, No. (%)b (n = 1329) (n = 809)
<25.0 452 (34.0) 291 (36.0)
25.0-29.9 358 (26.9) 229 (28.3)
≥30.0 519 (39.1) 289 (35.7)
Alcohol servings per wk, No. (%)b (n = 1347) (n = 820)
None 668 (49.6) 417 (50.9)
<1 263 (19.5) 165 (20.1)
1-7 288 (21.4) 167 (20.4)
>7 128 (9.5) 71 (8.7)
Sports physical activity, mean (SD)c 2.6 (1.0) 2.6 (1.0)
Attitudes toward menopause, mean (SD) 16.9 (2.8) 17.1 (2.7)
Symptom sensitivity at first annual follow-up, mean (SD) 10.4 (3.5) 10.3 (3.4)
Anxiety score ≥4, No. (%)b 488/1403 (34.8) 260/857 (30.3)
Perceived stress, mean (SD)b 8.3 (3.0) 8.1 (2.9)
Depressive symptoms on the CES-D Scale ≥16, No. (%)b 386/1383 (27.9) 193/834 (23.1)
Social support, mean (SD)b 12.5 (3.3) 12.7 (3.2)
Age at FMP, mean (SD), y – 51.6 (2.7)
Age, mean (SD), yd – 53.1 (3.2)
VMS cessation observed, No. (%) 505 (34.9) 414 (47.0)
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
CES-D, Center for Epidemiologic
Studies–Depression; FMP, final
menstrual period; VMS, vasomotor
symptoms.
a Totals may not sum to the heading
totals because of missing data on
some variables.
bAt first VMS report.
c At baseline.
dAt first post-FMP report of frequent
VMS.
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neredstatus, attitudes towardmenopause, andageat theFMP,
although statistical significance was sometimes lower be-
cause of smaller samples. Consistentwith total VMSduration
findings, post-FMP persistence was shorter for women with
later MT stage at first report of frequent VMS (Figure 3A) and
for Chinese and Japanese women (Figure 3B).
Factors related to total VMS duration or post-FMP persis-
tence in theadjustedmodels are summarized inTable 2. Ahaz-
ardratioexceeding1.0 indicatedagreater likelihoodofVMSces-
sation (reflecting a shorter total VMSduration associatedwith
that factorvswithout it), ahazardratioof less than1.0 indicated
a lesser likelihoodofVMScessation (reflecting longer totalVMS
duration associatedwith that factor vswithout it), and a haz-
ardratioof 1.0 indicatednodifference inVMSdurationfor those
with that factorvswithout it.Factors that remainedstatistically
significant inmultivariableanalyseswereearlierMTstage,per-
ceived stress, higher symptom sensitivity, lower educational
level, depressed symptoms at first report of VMS, longer total
VMSdurationobservedwith younger age, andAfricanAmeri-
can race/ethnicity (with shorter totalVMSduration forChinese
women). Similarly, associationsbetween longerpost-FMPper-
sistence andyounger age, earlierMT stage, lower educational
level,highersymptomsensitivity,moreanxiety,andgreaterper-
ceived stress also remained statistically significant in themul-
Figure 3. Kaplan-Meier Estimates of Post-FMP Persistence of Frequent VMS byMenopausal Transition Stage at First VMS Report
and by Race/Ethnicity
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Figure 2. Kaplan-Meier Estimates of Total VMSDuration of Frequent VMS byMenopausal Transition Stage at First VMS Report (A)
and by Race/Ethnicity (B)
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missing for 9 participants. Median duration for each group is calculated as the value on the x-axis corresponding to the intersection of the dashed horizontal line
(50%) with the group’s survival curve.
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tivariablemodel, asdid shorter totalVMSduration forChinese
women. In sensitivity analysesomittingwomenwith frequent
VMSat studyentry (whoweredisproportionatelyyounger and
at an earlierMT stage at the onset of VMS than otherwomen),
the resultingdistributionof totalVMSdurationwas lower,with
an overall median duration of 5.5 years. However, patterns of
associationof participant characteristicswere consistentwith
those in the full sample.
Discussion
Vasomotorsymptomsrepresenta frequent troublesomemidlife
experience amongmostwomen, butdata ondurationof these
menopausal symptomshavebeen lacking. SWANprovides the
strongest estimates to date of total VMSduration over theMT
andpost-FMPpersistence in amultiracial/multiethnic sample
Table 2. ReducedModels of the Adjusted HRs andMedians for Total VMSDuration and Post-FMP Persistencea
Predictor
Total VMS Duration
(n = 1368)
Post-FMP Persistence
(n = 772)
HR (95% CI)b
Median
Duration, y P Value HR (95% CI)b
Median
Persistence, y P Value
Age, yc
42.0-44.9 1 [Reference] >10.90
<.005
NAd NA
.05
45.0-49.9 2.43 (1.30-4.51) 9.34 1 [Reference]e 6.76
50.0-54.9 2.71 (1.44-5.09) 7.73 1.16 (0.84-1.60) 5.72
≥55.0 3.60 (1.78-7.29) 6.42 1.53 (1.05-2.24) 4.48
Menopausal transition stage
Premenopause 1 [Reference] >10.90
<.001
1 [Reference] >10.43
.001
Early perimenopause 2.04 (1.35-3.11) 10.06 1.48 (0.89-2.27) 6.61
Late perimenopause 3.55 (2.26-5.60) 6.12 2.16 (1.33-3.49) 4.47
Postmenopause 3.74 (2.34-5.98) 5.66 2.04 (1.27-3.28) 4.59
Race/ethnicity
Non-Hispanic white 1 [Reference] 9.01
<.008
1 [Reference] 5.43
.048
African American 0.75 (0.58-0.96) >10.90 0.79 (0.60-1.04) 6.88
Chinese 1.80 (1.17-2.76) 5.45 1.84 (1.14-2.95) 3.05
Hispanic 1.97 (0.56-6.92) 4.78 1.06 (0.19-5.84) 4.92
Japanese 1.00 (0.66-1.51) 9.34 0.91 (0.57-1.45) 5.77
Educational level ≥college
No 1 [Reference] 9.93
.03
1 [Reference] 6.54
.003
Yes 1.25 (1.03-1.52) 7.66 1.40 (1.13-1.74) 4.54
Symptom sensitivity at first annual follow-upf
Very low 1 [Reference] 7.36
.05
1 [Reference] 4.38
.049
Low 0.77 (0.58-1.00) 9.57 0.76 (0.56-1.04) 5.48
Moderate 0.85 (0.64-1.13) 8.22 0.78 (0.57-1.07) 5.45
High 0.64 (0.46-0.89) 10.81 0.58 (0.39-0.85) 8.47
Anxiety score ≥4c
No NA NA
NA
1 [Reference] 4.96
.02
Yes NA NA 0.73 (0.56-0.95) 7.40
Perceived stressc,g
Never or almost never 1 [Reference] 8.00
.02
1 [Reference] 4.92
.008
At least sometimes 0.75 (0.58-0.96) 10.78 0.70 (0.54-0.91) 8.13
Depressive symptoms on the CES-D Scale ≥16c
No 1 [Reference] 7.73
.005
NA NA
NA
Yes 0.66 (0.50-0.88) >10.90 NA NA
Abbreviations: CES-D, Center for Epidemiologic Studies–Depression; FMP, final
menstrual period; HR, hazard ratio; NA, not applicable; VMS, vasomotor
symptoms.
a Adjusted for all variables listed and for site. The total sample sizes are smaller
than those in Table 1 because of missing data for some covariates.
b Compared with the reference group, an HR exceeding 1.0 indicates shorter
duration, an HR of less than 1.0 indicates longer duration, and an HR of 1.0
indicates no difference in duration.
c At first VMS report for VMS duration and at first post-FMP report of frequent
VMS for post-FMP persistence.
d This variable was omitted in the backward elimination analysis.
e Because the number of women in the age category of 42.0 to 44.9 years was
very small for post-FMP persistence, the 2 lowest age categories were
combined so that the reference category was up to age 49.9 years.
f Very low is below themean −1 SD (<6.9), low is between themean and −1 SD
(7.0-10.4), moderate is between themean and 1 SD (10.5-13.8), and high is
above themean +1 SD (>13.8).
g A score between 5 and 10 is never or almost never, and a score between 11 and
25 is at least sometimes.
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of women. Among women who reported frequent VMS, the
median total VMS duration was 7.4 years, with VMS persist-
ing a median of 4.5 years after the FMP. African American
women had particularly persistent VMS, with a median total
VMS duration of 10.1 years. Compared with other similar in-
vestigations, SWANhas thebenefits of a larger andmultiracial/
multiethnic sample followed up for a longer period after the
FMPand inclusionofwomen reportingVMSat the first SWAN
visit,minimizing (butnot totally eliminating) truncationof ac-
tual total VMS duration.
Other cohort studieshave reported shorter13 and longer6,14
total VMS durations. TheMelbourneWomen’sMidlife Health
Project estimate of 5.2 years for total duration of bothersome
VMS may have been conservative because the investigation
largely comprised a sample of white race/ethnicity, with ex-
clusion of women reporting VMS at baseline and counting
women still having VMS at the last follow-up visit as no lon-
ger having VMS.13 In contrast, longer total VMS durations of
8.8 years6 and 10.2 years14were reported by the PennOvarian
Aging Study, which asked about VMS in the past year and re-
cruitedaconsiderablyyoungersampleatentry.Theonlystudy6
that examined totalVMSdurationafter theFMP foundamean
duration of 4.6 years formoderate to severe hot flashes, simi-
lar to our observation.
The best single predictor of both total VMS duration and
post-FMP persistence was beginning VMS at an earlier MT
stage.Womenwhoexperienced frequentVMSearly in theMT
had a significantly longer total VMS duration and, perhaps
counterintuitively,had longerpost-FMPpersistenceafter their
FMP. This finding is consistentwith other studies6,14 but pro-
vides stronger evidence given a longer duration of follow-up
after the FMP in the present study.
We observed pronounced racial/ethnic differences. Afri-
canAmericanwomenhad longer totalVMSduration, andChi-
neseandJapanesewomenhadshorter totalVMSduration.Only
one other study14 examined racial/ethnic influences on VMS
duration. In that smaller study of women of African Ameri-
can andnon-Hispanicwhite races/ethnicities, a similarly lon-
ger total VMS duration among African Americans was re-
ported. Shorter total VMS duration among Chinese and
Japanesewomen is consistent with research showing a lower
proportion of Asian women reporting hot flashes.5,38,39 The
physiologicalunderpinningsofethnic/racialdifferences in total
VMSduration are unknown to date.Womenwith greater BMI
had longer total VMS duration, broadly consistent with other
findings from SWAN indicating a greater likelihood of report-
inghot flasheswithhigher adiposity.5,15However, BMIwasno
longer significantly associatedwith total VMSdurationherein
inmultivariablemodelswhenconsidering factors suchas race/
ethnicity.
The observed higher degrees of perceived stress, anxiety,
depressive symptoms, and symptom sensitivity thatwere in-
dependently related to longer total VMS duration or longer
post-FMP persistence herein extend previous findings that
thesepsychological factorsarerelatedtoVMSprevalence.4,5,40-43
Pathways connecting negative affective factors and VMS are
likely complex and bidirectional.15,44-46 A direct physiological
link through the hypothalamic-pituitary-gonadal axis be-
tweennegative affective factors andVMShasbeenproposed47
but is not well tested.
The present study had several limitations. We may have
underestimated total VMS duration because VMS were mea-
sured annually and the time frame of inquiry was for the 2
weeks preceding the visit. Although prior work has indicated
that sensitivity and specificity for 2-week self-reported VMS
are high,48 we may have missed the onset of VMS or occur-
rencebecauseVMSfluctuateover time.49Consistentwithother
work,14 we required at least 2 consecutive HT-free and fre-
quent VMS–free study visits to define cessation of frequent
VMS, but VMSmay have reoccurred after the end of data col-
lection. Finally, despite up to 13 years of follow-up, some
women continued to report frequent VMS, so longer fol-
low-up is needed to better pinpoint the timing of cessation of
VMS.
Although duration and persistence of any VMS are
important to women and their health care professionals,
these analyses focus on total VMS duration and post-FMP
persistence of frequent VMS rather than any VMS for 2 main
reasons. First, frequent VMS are more bothersome and
more likely to influence women’s clinical decisions (such as
initiating treatment). Second, despite our lengthy follow-up,
well over half of the women who had any VMS continued to
experience them at follow-up visit 13, precluding estimation
of the median cessation. However, secondary analyses
showed that patterns of association between participant
characteristics and duration for any VMS were similar to
those for frequent VMS.
A major strength of our study is that SWAN is the largest
and longest longitudinal study to date reporting on total
VMS duration and post-FMP persistence. The longitudinal
nature and long-term follow-up are critical to obtain accu-
rate total VMS duration estimates. In contrast to prior
studies,6,13,14 we included women with frequent VMS at
baseline, who were all premenopausal or early perimeno-
pausal at the onset of frequent VMS and tended to have lon-
ger total VMS durations. The long follow-up also permitted
analyses of both total VMS duration and post-FMP persis-
tence. SWAN is unique in its capacity to study 5 racial/ethnic
groups, underscored by longer total VMS durations
observed in African American women. Finally, we examined
multiple predictors of total VMS duration and controlled for
various potential confounding variables that were collected
annually.
Conclusions
More than 50% of midlife women experience frequent VMS,
yet clinical guidelines typically underestimate their true du-
ration. Amongwomenwith frequent VMS, symptoms last for
approximately 7.4 years, they persist for approximately 4.5
years after theFMP, and they last the longest inAfricanAmeri-
can women. Specific characteristics related to longer-lasting
VMSincludedmutable factorssuchasanxiety,perceivedstress,
anddepressive symptoms.These findings canhelphealth care
professionals counsel patients about expectations regarding
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VMS and assist women in making treatment decisions based
on theprobability of theirVMSpersisting. In addition, theme-
dian total VMSduration of 7.4 years highlights the limitations
of guidance recommending short-term HT use and empha-
sizes theneed to identify safe long-termtherapies for the treat-
ment of VMS.
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